BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 1 hit Enz. Inhib. hit(s) with Target = 'Hexokinase-4' and Ligand = 'BDBM438001'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Hexokinase-4


(Homo sapiens (Human))
BDBM438001
PNG
(US10633348, Compound (A-1) | US10633348, Compound ...)
Show SMILES CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(Oc4cc(NC)ncn4)c3)cc2C(F)(F)F)CC1
Show InChI InChI=1S/C27H31F3N6O2/c1-4-35-9-11-36(12-10-35)16-20-7-8-21(14-22(20)27(28,29)30)34-26(37)19-6-5-18(2)23(13-19)38-25-15-24(31-3)32-17-33-25/h5-8,13-15,17H,4,9-12,16H2,1-3H3,(H,34,37)(H,31,32,33)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 31n/an/an/an/an/an/a



Dana-Farber Cancer Institute, Inc.

US Patent


Assay Description
The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...


US Patent US10633348 (2020)


BindingDB Entry DOI: 10.7270/Q22Z18JR
More data for this
Ligand-Target Pair